MBX Biosciences appoints Laurie Stelzer as independent director and audit committee chair

MBX Biosciences, Inc.

Laurie Stelzer appointed as Class I director effective Jan. 20, 2026, filling an existing board vacancy.
Stelzer will serve as chair of the Audit Committee, replacing Ed Mathers on that committee.
She brings CFO experience from Kailera, Orna, Mirati, Arena, Halozyme, and board roles at Sionna, PMV, Spyre.
Board size increased to eight directors; Stelzer is independent under Nasdaq standards.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.